• Home
  • Christine B. Boers-Doets
Christine B. Boers-Doets

Christine B. Boers-Doets
CancerMed Side Effects Institute · Department of Adverse Event Expertise Valorisation & Certification (V&C)

Dr.

About

36
Publications
17,472
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,744
Citations
Additional affiliations
August 2019 - present
CancerMed B.V.
Position
  • Managing Director
Description
  • My mission is to teach people that they can choose to take control of side effects. For many people dose adjustments are the first and only option that comes to mind when adverse events appear. Adverse events are manageable.
April 2008 - October 2019
Leiden University Medical Centre
Position
  • Researcher
September 1997 - May 2012
Waterland Hospital
Position
  • Project Manager

Publications

Publications (36)
Article
Full-text available
Purpose Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking and multiple care and management strategies are used. The main purpose of the present study is to gain information about the different skincare products being used against skin reactions in metastatic colorectal cancer (mCRC) and recurrent/meta...
Article
Targeted cancer therapies have fundamentally transformed the treatment of many types of cancers over the past decade, including breast, colorectal, lung, and pancreatic cancers, as well as lymphoma, leukemia, and multiple myeloma. The unique mechanisms of action of these agents have resulted in many patients experiencing enhanced tumor response tog...
Article
Full-text available
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of impr...
Article
Full-text available
Purpose: The objective of this sub-analysis of the BeCet study (NCT01136005) was to examine health-related quality of life (HRQoL) of patients experiencing dermatological adverse events (AEs) during the first 6 weeks of epidermal growth factor receptor inhibitor (EGFRI) treatment. Methods: Patients (n = 85) treated with EGFRI completed five ques...
Article
This is the protocol for a review and there is no abstract. The objectives are as follows: To examine the benefits (less severe AEs and improved HRQoL and adherence) and harms (more severe AEs, decreased HRQoL, and treatment discontinuation) of interventions (including patient education and pharmacological agents) for the treatment of people who ex...
Article
Full-text available
Cancer patients treated with targeted therapies (e.g., epidermal growth factor receptor inhibitors) are susceptible to dermatologic adverse events (AEs) including secondary skin infections. Whereas infections such as paronychia and cellulitis have been reported, nasal vestibulitis (NV) has not been described with the use of these agents. The aim of...
Article
Full-text available
Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and...
Article
Objectives To provide background information and management strategies for non-rash dermatological adverse events. Data Sources Peer-reviewed journal articles, professional manuals, online sources. Conclusion During the last decade, many dermatological adverse events of targeted therapy have been reported, including xerosis, skin fissures, prurit...
Article
Full-text available
Targeted anticancer therapies like epidermal growth factor receptor (EGFR) inhibitors, multitargeted tyrosine kinase inhibitors (mTKIs), and mammalian target of rapamycin (mTOR) inhibitors frequently result in dermatologic adverse events and mucosal adverse events, or, taken together, mucocutaneous adverse events. Mucocutaneous adverse events, incl...
Article
Full-text available
Regorafenib is an oral multikinase inhibitor that has shown antitumor activity in a range of solid tumors. Based on data from phase III clinical trials, regorafenib is indicated for the treatment of adult patients with metastatic colorectal cancer who have previously been treated with, or are not considered candidates for, other available therapies...
Article
Full-text available
With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles a...
Article
Full-text available
Targeted therapies such as epidermal growth factor receptor inhibitors, multi-targeted tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors have, to a greater or lesser extent, mucocutaneous adverse events (mcAEs) in common. Papulopustular rash, hand-foot skin reaction, and stomatitis are the most serious adverse events. A...
Article
Full-text available
Purpose The purpose of this study was to estimate the risk and severity of oral and gastrointestinal mucosal toxicities associated with selected targeted agents. Methods We searched the English-language literature in February 2011 for reports of randomized clinical trials comparing a FDA-approved targeted agent to a standard of care regimens. Long...
Chapter
This chapter focuses on various agents that are used against solid and hematopoietic tumors through distinct mechanisms of action. L-asparaginase catalyzes the conversion of L -asparagine to aspartic acid and ammonia, resulting in the depletion of asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susce...
Article
Full-text available
Radiation dermatitis (RD) results from radiotherapy and often occurs within the first 4 weeks of treatment, although late effects also occur. While RD may resolve over time, it can have a profound effect on patients' quality of life and lead to dose modifications. A study group of international, interdisciplinary experts convened to develop RD prev...
Article
e20669 Background: Mucocutaneous adverse events (mcAEs), including papulopustular rash, xerosis, pruritus, paronychia, hand-foot skin reaction, edema, taste alterations, oral pain and ulceration, hair-, periungual-, and ocular changes occur in the majority of patients during targeted anticancer therapies. Different mcAEs can be present with a varia...
Article
Purpose: The Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFRI-18) is a patient-reported outcomes questionnaire developed to assess the effect of EGFRI on patients. The FACT-EGFR-18 was translated into Dutch and evaluated in order to document that the translation adequately captures the concepts of t...
Article
Full-text available
Targeted drugs can result in a variety of skin toxicities that are unpleasant for patients and, if unattended to, can lead them to stop taking their drug as prescribed. Effective teamwork is required to ensure symptoms are identified and managed
Article
Full-text available
Purpose: The functional assessment of cancer therapy epidermal growth factor receptor inhibitor 18 (FACT-EGFRI-18) is a patient-reported outcomes questionnaire developed to assess the effect of EGFRI on health-related quality of life (HRQoL). Methods: Ten native-speaking residents of The Netherlands who reported EGFRI-associated mucocutaneous ad...
Article
Full-text available
Introduction mTOR inhibitor-associated stomatitis (mIAS) is a dose-limiting toxicity of mTOR inhibitors. Even small ulcerations can cause significant pain and affect quality of life. Scales developed for conventional oral mucositis are currently used to assess mIAS. These scales are mainly driven by ulceration size and the resulting impact on diet....
Article
Full-text available
Het aantal nieuwe, ‘doelgerichte’middelen voor de behandeling van kanker breidt zich snel uit en deze middelen nemen een steeds prominentere plaats in bij de behandeling van verschillende soorten kanker. Patiënten wordenmeestal ambulant en gedurende een langere periode (maanden tot jaren) behandeld. Ook de tandarts-algemeen practicus zal deze patië...
Article
Full-text available
Oral adverse events (OAEs) associated with multitargeted tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors (mTORIs) are underestimated but frequent and novel presentations of mucosal manifestations. Because optimal antitumor activity requires maintaining the optimal dose, it is essential to avoid unintended treatment de...
Article
This is the protocol for a review and there is no abstract. The objectives are as follows: To examine the benefits (less severe AEs and improved HRQoL and adherence) and harms (more severe AEs, decreased HRQoL, and treatment discontinuation) of interventions (including patient education and pharmacological agents) for the treatment of people who ex...
Article
The last decade in oncology has been highlighted by the emergence of novel, highly specific anti-cancer agents, targeting a variety of molecular structures and able to inhibit aberrantly activated oncogenic pathways. Epidermal growth factor receptor inhibitors (EGFRIs) represent one type of such "targeted" agents. Their use made treatment more tole...
Article
To provide oncology nurses with an overview of the toxicity management associated with the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab in patients with metastatic colorectal cancer. Monoclonal antibodies such as cetuximab and panitumumab that target EGFR have provided patients with metastatic colorec...
Article
Full-text available
Reacties aan huid, haar, nagels en ogen als gevolg van targeted therapie (TT) waren tot voor kort een nieuw fenomeen voor hulpverleners en patiënten. Er was onvoldoende kennis over preventieve en ondersteunende maatregelen voor deze zo zichtbare en hinderlijke bijwerking. Door het inzetten van succesvolle (en minder succesvolle) interventies is de...
Chapter
In dit boek worden de laatste nieuwe ontwikkelingen binnen de immuno- en targeted therapie beschreven. Per geneesmiddel wordt informatie gegeven over het werkingsmechanisme, de indicaties en wijze van toediening en wordt ingegaan op de bijwerkingen en de specifieke aandachtspunten voor de zorg. 'Immuno-/targeted therapie in de hemato-/oncologische...

Network

Cited By